Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Buy" from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given an average rating of "Buy" by the twelve ratings firms that are currently covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $60.73.

MIRM has been the subject of a number of research analyst reports. Raymond James restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. Finally, JMP Securities increased their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th.

Insider Activity

In other news, CEO Christopher Peetz sold 27,279 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the sale, the chief executive officer now owns 138,641 shares of the company's stock, valued at approximately $6,129,318.61. This trade represents a 16.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares of the company's stock, valued at approximately $214,698.35. The trade was a 92.25% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 92,764 shares of company stock valued at $4,109,161. 22.87% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC grew its stake in shares of Mirum Pharmaceuticals by 259.4% during the first quarter. CWM LLC now owns 593 shares of the company's stock worth $27,000 after purchasing an additional 428 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth $35,000. Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after purchasing an additional 278 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth $42,000.

Mirum Pharmaceuticals Stock Up 3.9%

MIRM opened at $46.38 on Friday. Mirum Pharmaceuticals has a 12 month low of $24.53 and a 12 month high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The stock has a market cap of $2.30 billion, a P/E ratio of -22.96 and a beta of 0.95. The stock's 50 day moving average price is $42.61 and its 200 day moving average price is $44.74.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. The business had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's revenue was up 61.2% compared to the same quarter last year. During the same period last year, the company posted ($0.54) EPS. As a group, research analysts predict that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.